Skip to main content
. 2023 Jun 29;11(6):e005584. doi: 10.1136/jitc-2022-005584

Figure 1.

Figure 1

SEA-CD40 plasma concentration versus time profiles for SEA-CD40 following intravenous administration every 3 weeks in patients with solid tumor malignancies and lymphomas. Arithmetic means are shown, with error bars depicting SD. (A) SEA-CD40 concentrations in patients with solid tumors in part A; (B) SEA-CD40 concentrations in patients with lymphomas in part C; (C) SEA-CD40 concentrations in patients with solid tumors after cycle 1 in part A; (D) SEA-CD40 concentrations in patients with lymphomas after cycle 1 in part C. LLOQ; lower limit of quantitation.